Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to compare the treatment outcomes of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT) for colorectal cancer liver metastases (CRLM) and to determine the favorable treatment modality according to tumor characteristics. Materials and methods: We retrospectively analyzed the records of 222 colorectal cancer patients with 330 CRLM who underwent RFA (268 tumors in 178 patients) or SBRT (62 tumors in 44 patients) between 2007 and 2014. Kaplan-Meier method and Cox models were used by adjusting with inverse probability of treatment weighting (IPTW). Results: The median follow-up duration was 30.5 months. The median tumor size was significantly smaller in the RFA group than in the SBRT group (1.5 cm vs 2.3 cm, p<0.001). In IPTW-adjusted analysis, difference in treatment modality was not associated with significant differences in 1-year and 3-year recurrence-free survival (35% vs 43%, 22% vs 23%; p=0.198), overall survival (96% vs 91%, 58% vs 56%; p=0.508), and freedom from local progression (FFLP; 90% vs 72%, 78% vs 60%; p=0.106). Significant interaction effect between the treatment modality and tumor size was observed for FFLP (p=0.001). In IPTW-adjusted subgroup analysis of patients with tumor size >2 cm, the SBRT group had a higher FFLP compared with the RFA group (HR, 0.153; p<0.001). Conclusion: SBRT and RFA showed similar local control in the treatment of patients with CRLM. Tumor size was an independent prognostic factor for local control and SBRT may be preferred for larger tumors.
Abstract
Purpose: This study aimed to compare the treatment outcomes of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT) for colorectal cancer liver metastases (CRLM) and to determine the favorable treatment modality according to tumor characteristics. Materials and methods: We retrospectively analyzed the records of 222 colorectal cancer patients with 330 CRLM who underwent RFA (268 tumors in 178 patients) or SBRT (62 tumors in 44 patients) between 2007 and 2014. Kaplan-Meier method and Cox models were used by adjusting with inverse probability of treatment weighting (IPTW). Results: The median follow-up duration was 30.5 months. The median tumor size was significantly smaller in the RFA group than in the SBRT group (1.5 cm vs 2.3 cm, p<0.001). In IPTW-adjusted analysis, difference in treatment modality was not associated with significant differences in 1-year and 3-year recurrence-free survival (35% vs 43%, 22% vs 23%; p=0.198), overall survival (96% vs 91%, 58% vs 56%; p=0.508), and freedom from local progression (FFLP; 90% vs 72%, 78% vs 60%; p=0.106). Significant interaction effect between the treatment modality and tumor size was observed for FFLP (p=0.001). In IPTW-adjusted subgroup analysis of patients with tumor size >2 cm, the SBRT group had a higher FFLP compared with the RFA group (HR, 0.153; p<0.001). Conclusion: SBRT and RFA showed similar local control in the treatment of patients with CRLM. Tumor size was an independent prognostic factor for local control and SBRT may be preferred for larger tumors.
참고문헌 (27)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- "Cancer stat facts: colorectal cancer" (2021)[URL]
- Hackl C, "Treatment of colorectal liver metastases in Germany : a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma", BMC Cancer, 14, pp.810~ (2014)
- Kopetz S, "Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy", J Clin Oncol, 27, pp.3677~3683 (2009)
- Venkat SR, "Colorectal liver metastasis : overview of treatment paradigm highlighting the role of ablation", AJR Am J Roentgenol, 210, pp.883~890 (2018)
- Chang DT, "Stereotactic body radiotherapy for colorectal liver metastases : a pooled analysis", Cancer, 117, pp.4060~4069 (2011)
- Scorsetti M, "Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver meta-stases from colorectal cancer", J Cancer Res Clin Oncol, 141, pp.543~553 (2015)
- Hoyer M, "Phase II study on stereotactic body radiotherapy of colorectal metastases", Acta Oncol, 45, pp.823~830 (2006)
- Wong SL, "American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer", J Clin Oncol, 28, pp.493~508 (2010)
- Ruers T, "Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial", J Natl Cancer Inst, 109, pp.djx015~ (2017)
- Tanis E, "Local recurrence rates after radiof-requency ablation or resection of colorectal liver metastases : analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983", Eur J Cancer, 50, pp.912~919 (2014)
- Mulier S, "Local recurrence after hepatic radiofrequency coagulation : multivariate meta-analysis and review of contributing factors", Ann Surg, 242, pp.158~171 (2005)
- Teratani T, "Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations", Hepatology, 43, pp.1101~1108 (2006)
- Komorizono Y, "Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation", Cancer, 97, pp.1253~1262 (2003)
- Joo JH, "Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer", Int J Radiat Oncol Biol Phys, 99, pp.876~883 (2017)
- Rusthoven KE, "Multi-institutional phase I", II trial of stereotactic body radiation therapy for liver metastases, 2009, pp.27, 1572~1578
- Jackson WC, "Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases", Int J Radiat Oncol Biol Phys, 100, pp.950~958 (2018)
- Wahl DR, "Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma", J Clin Oncol, 34, pp.452~459 (2016)
- Crocetti L, "Quality improvement guidelines for radiofrequency ablation of liver tumours", Cardiovasc Intervent Radiol, 33, pp.11~17 (2010)
- Kudo M, "Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010", Oncology, 78(Suppl 1), pp.113~124 (2010)
- Lencioni R, "Radiofrequency ablation of liver cancer", Tech Vasc Interv Radiol, 10, pp.38~46 (2007)
- McPartlin A, "Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases", Int J Radiat Oncol Biol Phys, 99, pp.388~395 (2017)
- van der Pool AE, "Stereotactic body radiation therapy for colorectal liver metastases", Br J Surg, 97, pp.377~382 (2010)
- Klement RJ, "Stereotactic body radiotherapy for oligo-metastatic liver disease : influence of pre-treatment chemotherapy and histology on local tumor control", Radiother Oncol, 123, pp.227~233 (2017)
- Klement RJ, "Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases", Radiother Oncol, 123, pp.218~226 (2017)
- Yang G, "The prognosis of radiofrequency ablation versus hepatic resection for patients with colorectal liver metastases : a systematic review and meta-analysis based on 22 studies", Int J Surg, 87, pp.105896~ (2021)
- Kim N, "Dose-response relationship in stereotactic body radiation therapy for hepatocellular carcinoma : a pooled analysis of an Asian Liver Radiation Therapy Group Study", Int J Radiat Oncol Biol Phys, 109, pp.464~473 (2021)